South Korea has consolidated its position as a leading player in pharmaceutical innovation, ranking third globally for drug development pipelines in 2026, behind only the US and China, according to industry data.

Eli Lilly has declined to list its diabetes treatment Mounjaro on Australia’s Pharmaceutical Benefits Scheme (PBS), despite a recommendation from the country’s medicines regulator, citing what it described as an unacceptably low pricing proposal from the federal government.

Analysts are looking ahead to the tafamidis patent trial involving Pfizer (NYSE: PFE), as recent court developments begin to shape investor expectations ahead of the proceedings next week.

Amneal Pharmaceuticals (AMRX) has agreed to acquire Kashiv BioSciences in a cash-and-stock transaction worth up to $1.1bn, in a move that will significantly expand the New Jersey drugmaker's position in the fast-growing biosimilars market.

The war in Iran has pushed up the retail price of widely used over-the-counter medicines in England by as much as 30 per cent, with pharmacists warning that further increases are likely unless key supply routes reopen.

AbbVie (ABBV) is to invest $1.4bn in a 185-acre pharmaceutical manufacturing campus in Durham, North Carolina, the company's largest single capital investment to date and its first significant foray into the state.

Adial Pharmaceuticals, the US clinical-stage biotech developing therapies for addiction disorders, has completed a demonstration manufacturing batch for its lead drug candidate AD04, clearing a technical prerequisite for the production of clinical and registration batches ahead of a planned phase 3 trial.

Europe faces a defining test of its ability to secure access to the latest innovative medicines, the head of the European Medicines Agency has warned, as US pricing policy pushes drugmakers to rethink where, when and at what price they bring new therapies to market.

Heights Capital Management, the San Francisco-based investment firm, has disclosed a 25.44 per cent stake in Faron Pharmaceuticals, the Finnish biotech, cementing its position as a dominant financial backer of the loss-making drug developer through a combination of direct shareholdings and convertible debt.

Pfizer is heading into one of the most consequential pharmaceutical patent battles of 2026 as the US drugmaker prepares to defend the intellectual property underpinning its tafamidis franchise, the cornerstone of its presence in the fast-growing market for transthyretin amyloid cardiomyopathy.